Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia.
Shuya FengYigang YuanZihan LinMin LiDaijiao YeLiuzhi ShiDanyang LiMin ZhaoChen MengXiaofei HeShanshan WuFang XiongSiyu YeJunjun YangHaifeng ZhuangLili HongShenmeng GaoPublished in: Experimental hematology & oncology (2024)
Our study first identify vulnerability to ferroptosis by regulating MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway. Combined treatment with HMAs and FINs provides a potential therapeutic choice for AML patients, especially for R/R-AML.
Keyphrases
- signaling pathway
- cell death
- low dose
- dna methylation
- acute myeloid leukemia
- end stage renal disease
- pi k akt
- skeletal muscle
- newly diagnosed
- epithelial mesenchymal transition
- chronic kidney disease
- gene expression
- peritoneal dialysis
- climate change
- cell proliferation
- combination therapy
- patient reported outcomes
- acute lymphoblastic leukemia
- copy number
- endoplasmic reticulum stress